-
1
-
-
0028041242
-
Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: A double-blind, placebo-controlled study. The International Gabapentin Study Group
-
Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia. 1994; 35: 795-801.
-
(1994)
Epilepsia
, vol.35
, pp. 795-801
-
-
Anhut, H.1
Ashman, P.2
Feuerstein, T.J.3
Sauermann, W.4
Saunders, M.5
Schmidt, B.6
-
2
-
-
0032800766
-
Gabapentin as add-on therapy in children with refractory partial seizures: A 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group
-
Appleton R, Fichtner K, LaMoreaux L, Alexander J, Halsall G, Murray G, Garofalo E. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia. 1999; 40: 1147-1154.
-
(1999)
Epilepsia
, vol.40
, pp. 1147-1154
-
-
Appleton, R.1
Fichtner, K.2
LaMoreaux, L.3
Alexander, J.4
Halsall, G.5
Murray, G.6
Garofalo, E.7
-
3
-
-
4644251930
-
-
Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004; 311: 324-333.
-
Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004; 311: 324-333.
-
-
-
-
4
-
-
4644328982
-
-
Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA. XP13512 [(+/-)-1-([(alpha- isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004; 311: 315-323.
-
Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA. XP13512 [(+/-)-1-([(alpha- isobutanoyloxyethoxy) carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004; 311: 315-323.
-
-
-
-
5
-
-
57449097189
-
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin
-
Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008; 48: 1378-1388.
-
(2008)
J Clin Pharmacol
, vol.48
, pp. 1378-1388
-
-
Cundy, K.C.1
Sastry, S.2
Luo, W.3
Zou, J.4
Moors, T.L.5
Canafax, D.M.6
-
6
-
-
0036159433
-
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine
-
Dresser GK, Bailey DG, Leake BF, Schwartz UI, Dawson PA, Freeman DJ, Kin RB. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002; 71: 11-20.
-
(2002)
Clin Pharmacol Ther
, vol.71
, pp. 11-20
-
-
Dresser, G.K.1
Bailey, D.G.2
Leake, B.F.3
Schwartz, U.I.4
Dawson, P.A.5
Freeman, D.J.6
Kin, R.B.7
-
7
-
-
0031858744
-
Gabapentin bioavailability: Effect of dose and frequency of administration in adult patients with epilepsy
-
Gidal BE, DeCerce J, Bockbrader HN, Gonzalez J, Kruger S, Pitterle M, Rutecki P, Eugene Ramsay R. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 1998; 31: 91-99.
-
(1998)
Epilepsy Res
, vol.31
, pp. 91-99
-
-
Gidal, B.E.1
DeCerce, J.2
Bockbrader, H.N.3
Gonzalez, J.4
Kruger, S.5
Pitterle, M.6
Rutecki, P.7
Eugene Ramsay, R.8
-
8
-
-
0034129145
-
Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability
-
Gidal BE, Radulovic LL, Kruger S, Rutecki P, PitterleM, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000; 40: 123-127.
-
(2000)
Epilepsy Res
, vol.40
, pp. 123-127
-
-
Gidal, B.E.1
Radulovic, L.L.2
Kruger, S.3
Rutecki, P.4
Pitterle, M.5
Bockbrader, H.N.6
-
9
-
-
0027454448
-
Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy
-
Goa KL, Sorkin EM. Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs. 1993; 46: 409-427.
-
(1993)
Drugs
, vol.46
, pp. 409-427
-
-
Goa, K.L.1
Sorkin, E.M.2
-
10
-
-
33646100289
-
Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoAreductase inhibitor, in rats and healthy human subjects
-
Koitabashi Y, Kumai T, Matsumoto N, Watanabe M, Sekine S, Yanagida Y, Kobayashi S. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoAreductase inhibitor, in rats and healthy human subjects. Life Science. 2006; 78: 2852-2859.
-
(2006)
Life Science
, vol.78
, pp. 2852-2859
-
-
Koitabashi, Y.1
Kumai, T.2
Matsumoto, N.3
Watanabe, M.4
Sekine, S.5
Yanagida, Y.6
Kobayashi, S.7
-
11
-
-
0030727097
-
Failure of absorption of gabapentin after rectal administration
-
Kriel RL, Birnbaum AK, Cloyd JC, Ricker BJ, Jones Saete C, Caruso KJ. Failure of absorption of gabapentin after rectal administration. Epilepsia. 1997; 38: 1242-1244.
-
(1997)
Epilepsia
, vol.38
, pp. 1242-1244
-
-
Kriel, R.L.1
Birnbaum, A.K.2
Cloyd, J.C.3
Ricker, B.J.4
Jones Saete, C.5
Caruso, K.J.6
-
12
-
-
61549121079
-
XP052 Study Group. Randomized, double-blind, placebo-controlled study of XP-13512/GSK1838262 in patients with RLS
-
Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW; XP052 Study Group. Randomized, double-blind, placebo-controlled study of XP-13512/GSK1838262 in patients with RLS. Neurology. 2009; 72: 439-446.
-
(2009)
Neurology
, vol.72
, pp. 439-446
-
-
Kushida, C.A.1
Becker, P.M.2
Ellenbogen, A.L.3
Canafax, D.M.4
Barrett, R.W.5
-
13
-
-
85036795391
-
-
Lal R, Sukbuntherng J, Luo W, Jacob Huff F, Blumenthal R, Cundy KC. Adouble-blind, placebo-controlled, dose escalation study of the pharmacokinetics of oral XP13512 in healthy adults. Presented at American Association of Pharmaceutical Scientists 2008, Baltimore, US. Sleep. 2008; 31 (Suppl): 267 (abstract 0815).
-
Lal R, Sukbuntherng J, Luo W, Jacob Huff F, Blumenthal R, Cundy KC. Adouble-blind, placebo-controlled, dose escalation study of the pharmacokinetics of oral XP13512 in healthy adults. Presented at American Association of Pharmaceutical Scientists 2008, Baltimore, US. Sleep. 2008; 31 (Suppl): 267 (abstract 0815).
-
-
-
-
14
-
-
1542346411
-
Orange juice substantially reduces the bioavailability of the β-adrenergic-blocking agent celiprolol
-
Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the bioavailability of the β-adrenergic-blocking agent celiprolol. Clin Pharmacol Ther. 2004; 75: 184-190.
-
(2004)
Clin Pharmacol Ther
, vol.75
, pp. 184-190
-
-
Lilja, J.J.1
Juntti-Patinen, L.2
Neuvonen, P.J.3
-
15
-
-
27644463532
-
Effects of orange juice on the pharmacokinetics of atenolol
-
Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol. 2005; 61: 337-340.
-
(2005)
Eur J Clin Pharmacol
, vol.61
, pp. 337-340
-
-
Lilja, J.J.1
Raaska, K.2
Neuvonen, P.J.3
-
16
-
-
0029057902
-
Gabapentin
-
McLean MJ. Gabapentin. Epilepsia. 1995; 36 (Suppl): 73-86.
-
(1995)
Epilepsia
, vol.36
, Issue.SUPPL.
, pp. 73-86
-
-
MJ, M.1
-
17
-
-
0032819783
-
Gabapentin in the management of convulsive disorders
-
McLean MJ. Gabapentin in the management of convulsive disorders. Epilepsia. 1999; 40(Suppl): 39-50.
-
(1999)
Epilepsia
, vol.40
, Issue.SUPPL.
, pp. 39-50
-
-
MJ, M.1
-
18
-
-
0034750718
-
Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study
-
Rice AS, Maton S; Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001; 94: 215-224.
-
(2001)
Pain
, vol.94
, pp. 215-224
-
-
Rice, A.S.1
Maton, S.2
-
19
-
-
0032477305
-
Gabapentin for the treatment of postherpetic neuralgia: A randomized, controlled trial
-
Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized, controlled trial. JAMA. 1998; 280: 1837-1842.
-
(1998)
JAMA
, vol.280
, pp. 1837-1842
-
-
Rowbotham, M.1
Harden, N.2
Stacey, B.3
Bernstein, P.4
Magnus-Miller, L.5
-
20
-
-
0032883045
-
Effects of food on clinical pharmacokinetics
-
Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999; 37: 213-255.
-
(1999)
Clin Pharmacokinet
, vol.37
, pp. 213-255
-
-
BN, S.1
-
21
-
-
0031028878
-
Colonic absorption of antiepileptic agents
-
Stevenson CM, Kim J, Fleisher D. Colonic absorption of antiepileptic agents. Epilepsia. 1997; 38: 63-67.
-
(1997)
Epilepsia
, vol.38
, pp. 63-67
-
-
Stevenson, C.M.1
Kim, J.2
Fleisher, D.3
-
22
-
-
0027402753
-
A saturable transport mechanismin the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma
-
Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanismin the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res. 1993; 10: 276-281.
-
(1993)
Pharm Res
, vol.10
, pp. 276-281
-
-
Stewart, B.H.1
Kugler, A.R.2
Thompson, P.R.3
Bockbrader, H.N.4
-
23
-
-
0027374164
-
Gabapentin as add-on therapy in refractory partial epilepsy: A double-blind, placebo-controlled, parallel-group study
-
The US Gabapentin Study Group No 5
-
The US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology. 1993; 43: 2292-2298.
-
(1993)
Neurology
, vol.43
, pp. 2292-2298
-
-
-
24
-
-
0025343921
-
Gabapentin in partial epilepsy
-
UK Gabapentin Study Group
-
UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet. 1990; 335: 1114-1117.
-
(1990)
Lancet
, vol.335
, pp. 1114-1117
-
-
|